paroxetine


Also found in: Dictionary, Thesaurus, Wikipedia.

paroxetine

 [pah-rok´sĕ-tēn]
a selective serotonin reuptake inhibitor administered orally as the hydrochloride salt as an antidepressant and to treat obsessive-compulsive, panic, and social anxiety disorders.

paroxetine

(pă-rŏk′sĭ-tēn′)
n.
A drug of the SSRI class, C19H20FNO3, used in its hydrochloride form to treat depression, anxiety, and certain other disorders, including obsessive-compulsive disorder.

paroxetine

A SEROTONIN RE-UPTAKE INHIBITOR drug. A brand name is Seroxat.
References in periodicals archive ?
Keywords: Paroxetine orodispersible films, Solvent casting method, Superdisintegrants, Hydroxypropyl methylcellulose, Poly vinyl alcohol.
Paroxetine can decrease the NOS levels, and tadalafil works in the NO cascade to increase levels of downstream products.
We agree with GSK that federal law prevented GSK from adding a warning about the alleged association between paroxetine and suicides in adults.
In the midst of the study, 7(7/4%) patients discontinued due to adverse effects as well as 17 (3/11%) patients (1 case in the paroxetine group and 16 cases in the placebo group) due to the ineffectiveness of treatment.
Paroxetine and HJDT (2 and 4 g/kg) treatment reversed the decrease of sucrose consumption ratio at day 43 after the CUS.
The changes in morphology of isolated stem cell and neurogenic induced cells were analyzed following the Paroxetine exposure for 2, 4 and 6 days.
Only 5 trials reported patients' self-rated depression symptom severity (in patients taking fluoxetine and paroxetine) and none reported improvement.
Results: The percent responses with acetylcholine, serotonin and paroxetine were 100, 158.7 and 6.45 percent respectively indicating that acetylcholine and serotonin causes an increase in contractility of isolated ileal smooth muscle in comparison to paroxetine which has a depressant effect on motility.
Before that litigation went to trial, GUK and Alpharma each entered into agreements with GSK, which included terms prohibiting their independent entry into the UK paroxetine market.
Patients received 20-40 mg paroxetine once daily, 200-300 mg imipramine once daily, or placebo.
Exposures included the use of citalopram, escitalopram, fluoxetine, paroxetine, or sertraline in the month before through the third month of pregnancy (BMJ 2015;350:h3190 [doi:10.1136/bmj.h3190]).
In this trial we use paroxetine as the active comparator drug because it is a widely used first-line treatment for MDD with proven efficacy and safety that is often used as a positive control drug in Phase 2 and Phase 3 clinical trials.